XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
 Clinical Trials
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Nov 18, 2006 - 1:55:25 PM

Scleroderma Channel
subscribe to Scleroderma newsletter

Latest Research : Rheumatology : Scleroderma

   DISCUSS   |   EMAIL   |   PRINT
Cyclophosphamide Improves Breathing for Scleroderma Patients
Jul 10, 2006 - 6:44:00 AM, Reviewed by: Dr. Priya Saxena

"We assessed their pulmonary function every three months to
determine their forced vital capacity regarding breathing, and then closely followed the patients for one year thereafter."

An oral medication improves overall lung function and reduces lung-related inflammation associated with the deadly skin disease scleroderma, says a researcher at the University of Medicine and Dentistry of New Jersey who was part of a national study.

The 12-month, 13-site clinical trial involved 158 patients treated with the drug cyclophosphamide. The oral medication had a modest but significant effect on the lung functions of scleroderma patients stricken with alveolitis, a chronic inflammation of the lung tissue commonly diagnosed in those with systemic scleroderma, said Dr. Vivien
M. Hsu, a scleroderma specialist at the UMDNJ-Robert Wood Johnson Medical School in New Brunswick and a principal investigator in the study.

Subjects with dyspnea, or breathlessness due to interstitial lung disease, also felt better after being given daily doses of cyclophosphamide for one year, Dr. Hsu said. The study was published recently (June 22, 2006) in the New England Journal of Medicine.

"We used a double-blind, randomized, placebo-controlled clinical trial to determine the drug's ability to suppress labored breathing and restrictive lung physiology in these patients," Dr. Hsu said. "We assessed their pulmonary function every three months to
determine their forced vital capacity regarding breathing, and then closely followed the patients for one year thereafter."

The patients in the study received 2 milligrams per kilogram of body weight each day, or matching placebo, for one year. The forced vital capacity measured in these subjects at the end of two years remained stable in the majority of patients who received cyclophosphamide.

Scleroderma is a rheumatic disease that primarily affects women, and is characterized by skin thickening due to over-production of scar (collagen) and connective tissue. This disease often scars the organs, including the lungs, kidneys, gastro-intestinal tract and heart. Scleroderma frequently can damage the smallest blood vessels leading to
further damage of these vital organs.

The cause of the disease is unknown but it is widely regarded by medical experts as an autoimmune disorder. There are no proven drugs that may reverse the damage due to scleroderma-related interstitial lung disease. Different drugs may be used to treat its manifestations, but patients whose vital organs are attacked and adversely affected by
scleroderma may die from complications of this unpredictable disease.

- Study Published in New England Journal of Medicine


Subscribe to Scleroderma Newsletter
E-mail Address:


UMDNJ is the nation's largest free-standing public health sciences university with more than 5,500 students attending the state's three medical schools, its only dental school, a graduate school of biomedical sciences, a school of health related professions, a school of nursing and its only school of public health, on five campuses. Last year, there were more than two million patient visits to UMDNJ facilities and faculty at campuses in Newark, New Brunswick/Piscataway, Scotch Plains, Camden and Stratford. UMDNJ operates University Hospital, a Level 1 Trauma Center in Newark, and University Behavioral HealthCare, a mental health and addiction services network.

Related Scleroderma News
Cyclophosphamide Improves Breathing for Scleroderma Patients

For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page


© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us